Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (<scp>W</scp>est <scp>J</scp>apan <scp>O</scp>ncology <scp>G</scp>roup 5910L): An open‐label, randomized, phase 2 trialMasayuki Takeda, Isamu Okamoto, Haruko Daga et al.|Cancer|2016Cited by 42
Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non–Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505Isamu Okamoto, Kazuhiko Nakagawa, Takashi Nishimura et al.|Clinical Cancer Research|2008Cited by 26
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA StudyYasunori Murata, Nobuhiko Seki, Shigeru Tanzawa et al.|JTO Clinical and Research Reports|2023Cited by 5
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.Masayuki Takeda, Takashi Seto, Hidetoshi Hayashi et al.|Journal of Clinical Oncology|2015Cited by 3